Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2

מצבים רפואיים

Prostate CA

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • BC Cancer Radiation Oncology, Surrey, British Columbia, Canada

    Contact: Study coordinator (Cathy Tran) · 250 519 5500
    Contact: Study coordinator (Winkle Kwan, MD FRCPC) · wkwan@bccancer.bc.ca · 604 587 4340
    Contact: Principal Investigator (Winkle Kwan, MD FRCPC)
    Anand Karvat, MD FRCPC (Sub-investigator)
    Arthur Cheung, MD FRCPC (Sub-investigator)
    Bernard Lee, MD FRCPC (Sub-investigator)
    Dylan Narinesingh, MD FRCPC (Sub-investigator)
    Jui-Chih Cheng, MD FRCPC (Sub-investigator)
    Ka-Kit David Yeung, MD FRCPC (Sub-investigator)
  • BC Cancer Radiation Oncology, Victoria, British Columbia, Canada

    Contact: Study coordinator (Abraham Alexander) · aalexander3@bccancer.bc.ca
    Contact: Study coordinator (Winkle Kwan) · wkwan@bccancer.bc.ca · 604 587 4340
    Contact: Principal Investigator (Abraham Alexander)
    Sonia Murchison (Sub-investigator)
    Howard Pai (Sub-investigator)
    Jordan Wong (Sub-investigator)
    Saibishkumar Parameswaren (Sub-investigator)
    Abdulla Al-Rashdan (Sub-investigator)
מובילי המחקר
  • Abraham Alexander

    Principal Investigator

    BC Cancer

  • Winkle Kwan

    Principal Investigator

    BC Cancer